

## H. Lundbeck A/S

Ottiliavej 9  
DK-2500 Valby, Copenhagen  
CVR number: 56759913  
LEI code: 5493006R4KC2OI5D3470

Tel +45 36 30 13 11  
Fax +45 36 43 82 62

E-mail investor@lundbeck.com  
www.lundbeck.com



## Corporate Release

### Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

**Valby, Denmark, 25 August 2017** – H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck.

<b>1.</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>		
a)	Name	Anders Gersel Pedersen	
<b>2.</b>	<b>Reason for the notification</b>		
a)	Position/status	Executive Vice President, Research & Development	
b)	Initial notification/Amendment	Initial notification	
<b>3.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	H. Lundbeck A/S	
b)	LEI code	5493006R4KC2OI5D3470	
<b>4.A</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument	Shares	
	Identification code	DK 0010287234	
b)	Nature of the transaction	Sale of shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		387.66	150,000
d)	Aggregated information - Aggregated volume - Price		
e)	Date of the transaction	2017-08-23	
f)	Place of the transaction	NASDAQ Copenhagen XCSE	

<b>4.B</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument	Shares	
	Identification code	DK 0010287234	
b)	Nature of the transaction	Sale of shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		394.85	50,000
d)	Aggregated information - Aggregated volume - Price		
e)	Date of the transaction	2017-08-24	
f)	Place of the transaction	NASDAQ Copenhagen XCSE	

<b>1.</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>		
a)	Name	Anders Götzsche	
<b>2.</b>	<b>Reason for the notification</b>		
a)	Position/status	Executive Vice President & Chief Financial Officer	
b)	Initial notification/Amendment	Initial notification	
<b>3.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	H. Lundbeck A/S	
b)	LEI code	5493006R4KC2OI5D3470	
<b>4.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument	Shares	
	Identification code	DK 0010287234	
b)	Nature of the transaction	Sale of shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		387.66	240,000
d)	Aggregated information - Aggregated volume - Price		



e)	Date of the transaction	2017-08-23
f)	Place of the transaction	NASDAQ Copenhagen XCSE

Persons under an obligation to report are defined as members of the Executive Management, members of the Board of Directors and other executives of H. Lundbeck A/S and persons/entities closely associated to them.

Closely associated persons/entities means inter alia:

- spouse or cohabitant
- dependent children
- legal entities in which the executive has a controlling influence.

### Lundbeck contacts

Investors:

Palle Holm Olesen  
Vice President, Investor Relations  
[palo@lundbeck.com](mailto:palo@lundbeck.com)  
+45 30 83 24 26

Media:

Mads Kronborg  
Senior Director, Corp. Communication  
[mavk@lundbeck.com](mailto:mavk@lundbeck.com)  
+45 36 43 40 00

### About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are Alzheimer's disease, depression, Parkinson's disease and schizophrenia.

Our approximately 5,000 employees in 55 countries are engaged in the entire value chain throughout research, development, manufacturing, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have production facilities in Denmark, France and Italy. Lundbeck generated revenue of DKK 15.6 billion in 2016 (EUR 2.1 billion; USD 2.2 billion).

For additional information, we encourage you to visit our corporate site [www.lundbeck.com](http://www.lundbeck.com) and connect with us on Twitter at @Lundbeck.